| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/17/2005 | WO2005013899A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 02/17/2005 | WO2005013884A2 Methods for preventing neurological events |
| 02/17/2005 | WO2005013800A2 Elevated hedgehog pathway activity in digestive system tumors, and methods of treating digestive system tumors having elevated hedgehog pathway activity |
| 02/17/2005 | WO2004108883A3 Transducible dna-binding proteins |
| 02/17/2005 | WO2004108763A3 Mutants of the factor vii epidermal growth factor domain |
| 02/17/2005 | WO2004106369A3 Complement inhibitors from ticks |
| 02/17/2005 | WO2004099135A3 Hiv prodrugs cleavable by cd26 |
| 02/17/2005 | WO2004091592A3 Methods and compositions to treat myocardial conditions |
| 02/17/2005 | WO2004091551A3 Anti-tumor vasculature effects of human serum albumin derivatives |
| 02/17/2005 | WO2004089395A3 Use of an inhibitor of cathepsin-s or -b to treat or prevent chronic obstructive pulmonary disease |
| 02/17/2005 | WO2004089278A3 Sexual hygienic composition |
| 02/17/2005 | WO2004083398A3 Therapeutic uses of hmgn1 and hmgn2 |
| 02/17/2005 | WO2004083236A3 Cancer treatment using proanp peptides |
| 02/17/2005 | WO2004078061B1 Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using luteinizing hormone |
| 02/17/2005 | WO2004065600A3 Rna interference by palindromic or modified rna molecules |
| 02/17/2005 | WO2004060272A3 Delivery of peroxide-generating enzymes to the vaginal tract |
| 02/17/2005 | WO2004053453A3 Modulation of bub 1-beta expression |
| 02/17/2005 | WO2004047740A3 Composition and method for treating lupus nephritis |
| 02/17/2005 | WO2004046310A3 Novel mouse polypeptides encoded by polynucleotides and methods of their use |
| 02/17/2005 | WO2004044226A3 Induction of cellular senescence by cdk4 disruption for tumor supression and regression |
| 02/17/2005 | WO2004044126A3 Novel proteins and their uses |
| 02/17/2005 | WO2004041181A3 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration |
| 02/17/2005 | WO2004021967A3 Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
| 02/17/2005 | WO2004020457A3 Methods and compositions for the inhibition of dna repair protein xrcc-3 |
| 02/17/2005 | WO2004014937A3 Thrombin peptide derivatives |
| 02/17/2005 | WO2004009028A3 Method and composition for treating and preventing influenza infection and symptoms thereof |
| 02/17/2005 | WO2004002999A8 Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |
| 02/17/2005 | WO2003101396A3 Helper virus-free herpesvirus amplicon particles and uses thereof |
| 02/17/2005 | WO2003082019A9 Peptides with anti-hypertensive properties |
| 02/17/2005 | WO2003070916A3 Dna encoding snorf44 receptor |
| 02/17/2005 | WO2003070910A3 INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 02/17/2005 | WO2003062373A3 Methods and materials for the recruitment of endothelial cells |
| 02/17/2005 | WO2003050258A3 Endogenous retrovirus polypeptides linked to oncogenic transformation |
| 02/17/2005 | WO2003050246A3 Antisense modulation of nod1 expression |
| 02/17/2005 | WO2003038051A3 Method of inducing apoptosis in hyperproliferative cells |
| 02/17/2005 | WO2003033675A3 Identification of binding partners for specific proteins |
| 02/17/2005 | WO2003025131A3 Protein modification and maintenance molecules |
| 02/17/2005 | WO2002088304A3 Compositions and methods for suppressing immune responses |
| 02/17/2005 | WO2002074913A3 Nucleic acid-associated proteins |
| 02/17/2005 | US20050039232 DNA molecules and polypeptides of Pseudomonas syringae Hrp pathogenicity island and their uses |
| 02/17/2005 | US20050038233 obtaining a sequence-defined molecular weight markers that provide an accurate and robust calibration set for determinations of molecular weight of production batches; subjecting the molecular weight markers to column chromatography to establish a relationship between retention time and molecular weight |
| 02/17/2005 | US20050038230 For decreasing food intake; eating disorders; sexual disorders |
| 02/17/2005 | US20050038126 Administering mammal a bicyclo [3.2.1]octan in a double ring system having kaurene structure such as steviol, isosteviol and stevioside; synergistic mixture with soy protein, and/or fiber and/or isoflavone |
| 02/17/2005 | US20050038121 Abuse resistant lysine amphetamine compounds |
| 02/17/2005 | US20050038109 treatment of solid tumor cancers |
| 02/17/2005 | US20050038029 Transferring, releasing nitric oxide; side effect reduction; using a compound containing nitrosos group |
| 02/17/2005 | US20050038012 use in improvement of gastrointestinal blood flow, in treatment of hypertension and in treatment and prophylaxis of cardiac damages induced by adriamycin and comparable anti-cancer drugs |
| 02/17/2005 | US20050038008 Drug for preventing vascular restenosis and instrument to be embedded in vessel coated with the drug |
| 02/17/2005 | US20050037989 Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo |
| 02/17/2005 | US20050037987 Methods of identifying kinases and uses thereof |
| 02/17/2005 | US20050037986 p53 treatment of papillomavirus and carcinogen-transformed cells in hyperplastic lesions |
| 02/17/2005 | US20050037983 Compositions and methods for the treatment of depression and other affective disorders |
| 02/17/2005 | US20050037977 Compounds for treating tumors |
| 02/17/2005 | US20050037976 Hematopoietic stimulation |
| 02/17/2005 | US20050037974 E-Ca R Cb-A, in which E is a diagnostic agent, R is a reactive group, Cb and Ca are optional first and second connecting groups, and A is an affinity group that is any molecule or part of a molecule possessing specific binding determinants for a target molecule |
| 02/17/2005 | US20050037973 Compounds and methods for cancer therapy |
| 02/17/2005 | US20050037972 Bactericides; using polypeptides |
| 02/17/2005 | US20050037971 Use of hepcidin as a regulator of iron homeostasis |
| 02/17/2005 | US20050037970 Protein devived from Schistosome parasites |
| 02/17/2005 | US20050037969 Molecular interactions in hematopoietic cells |
| 02/17/2005 | US20050037968 Peptide leukotriene receptor |
| 02/17/2005 | US20050037967 conjugate is cytotoxic to cells expressing more than 2000 type 2 VEGF receptors per celll fusion protein with cytotoxic molecule such as gelonin or granzyme B or Bax |
| 02/17/2005 | US20050037966 Keratinocyte growth factor-2 |
| 02/17/2005 | US20050037965 Use of PAK inhibitor for the treatment of a joint disease |
| 02/17/2005 | US20050037964 Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity |
| 02/17/2005 | US20050037963 Methods of regulating focal adhesion kinase and its associated cellular functions by fak family-interacting protein |
| 02/17/2005 | US20050037962 Modulating angiogenesis by modulating gene expression or activation of syndecan-2; antitumor agents |
| 02/17/2005 | US20050037961 Generation, maintenance vascular system tissue; controlling gene expression; cardiovascular disorders |
| 02/17/2005 | US20050037959 Low white blood cell titer |
| 02/17/2005 | US20050037958 Therapy for kidney and congestive heart failure; nephrotic syndrome; pulmonary edema; hypotensive agents; adjust urine flow |
| 02/17/2005 | US20050037957 Polypeptide as target of drugs to detect central nervous system disorders, cancer, metabolism and cardiovascular disorders |
| 02/17/2005 | US20050037956 Screening method for agents useful in treating diabetes |
| 02/17/2005 | US20050037955 Bactericides; fungicides; isolated polypeptides; inflammatory bowel disorders; infections |
| 02/17/2005 | US20050037954 Novel agents for ameliorating motor disorder |
| 02/17/2005 | US20050037953 Aspartyl protease inhibitor; antimalaria agents |
| 02/17/2005 | US20050037951 Composition and methods for treatment of sexual dysfunction |
| 02/17/2005 | US20050037950 N1-modified glycopeptides |
| 02/17/2005 | US20050037949 Mannose binding lectin and uses thereof |
| 02/17/2005 | US20050037948 Calcium phosphopeptide complexes |
| 02/17/2005 | US20050037494 Using antisense agents to reduce and/or prevention genic expression associated with cardi-vascular complications; gene therapy |
| 02/17/2005 | US20050037475 Method of purifying TFPI and TFPI analogs |
| 02/17/2005 | US20050037469 Fusion polypeptide comprising a collagen-binding domain and an epithelial cell proliferation-modulating domain for use as tool in regenerative medicine and tissue repair |
| 02/17/2005 | US20050037468 Expression vector comprising nucleotide sequences coding g protein coupled receptor for use in identifying modulator for use in treatment and prevention of pain; antinociceptive agents |
| 02/17/2005 | US20050037467 83 human secreted proteins |
| 02/17/2005 | US20050037466 Membrane protein for use in identifying modulators for prevention and treatment of diagnosis, treatment, and prevention of neurological, immunological and cell proliferative disorders |
| 02/17/2005 | US20050037464 Prokineticin polypeptides, related compositions and methods |
| 02/17/2005 | US20050037463 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 02/17/2005 | US20050037462 Expression vector comprising nucleotide sequences coding g protein for use in generating immunoglobulins for use in prevention, treatment and diagnosis of cell proliferative disorders |
| 02/17/2005 | US20050037460 Potassium channels and genes encoding these potassium channels |
| 02/17/2005 | US20050037455 Expression vector comprising antisense nuclelotide sequence which decrease exxpression from kinase suppressor of RAS (KRAS) for use in the treatment and prevention of cell proliferative disorders |
| 02/17/2005 | US20050037449 Agent for controlling circadian rhythm disorder |
| 02/17/2005 | US20050037445 analyzing molecules expressed on the cell surface of cancer cells and comparing to nonmalignant cells; screening for cancer specific promoters to be used singly or in combination for delivery and expression of therapeutic genes for treatment of cancer |
| 02/17/2005 | US20050037432 Macroglobulin peptides for use as diagnostic indicator of osteoarthritis, bone and tissue disorders |
| 02/17/2005 | US20050037430 creating a peptide database by screening, analyzing the results, characterizing a physical, chemical, or biological property of the peptides, recording; using a computer for presenting biomolecular sequence data; regulatory activity on pro- or anti-inflammatory cytokine cascades; immunoresponse |
| 02/17/2005 | US20050037422 Synthetic peptides and dna sequences for treatment of multiple sclerosis |
| 02/17/2005 | US20050037419 Compositions and methods relating to lung specific genes and proteins |
| 02/17/2005 | US20050037416 Hybrid nucleic acid; isolation antibody |
| 02/17/2005 | US20050037412 Thermostable Taq polymerase fragment |
| 02/17/2005 | US20050037404 Methods of modulating drug clearance mechanisms by altering SXR activity |
| 02/17/2005 | US20050037395 Product |